RE:One more look at the new 90 day optimized dataNice post Eoganacht. Thanks for sharing.
________________________________
Eoganacht - (4/18/2022 5:44:29 PM)
One more look at the new 90 day optimized data
I changed the percentages to patient counts for the recent 90 day numbers for the:
23 patients enrolled and treated in Study II who received an optimized primary study treatment
CR = 12
PR = 4
Pending = 3
NR = 4
Potential CR = 82%
In the last newsletter there were 18 post-Aug 20 2020 optimized patients
CR = 8
PR = 2
Pending = 7
NR = 1
Potential CR = 94.4%
In the period between the two news releases 7 patients reached 90 days and 5 more patients were treated for a total of 12 patients. Of these 12 patients there were:
CR = 4
PR = 2
Pending = 3
NR = 3
Potential CR = 75%
Out of these 12 patients 3 patients (25%) were NR. The results of just these 3 patients accounts for the drop in 90 day potential CR. We will probably never know what happened with these 3 probably very sick and elderly patients but given where we are in the trial it will likely have little overall effect. If you flip a coin 12 times you won't likely get 6 heads and 6 tails. You might get 4 tails and 8 heads. But if you fip a coin 100 times it will be much closer to 50% heads and 50% tails. If those 3 patients had been CR or PR we would have a 90 day potential CR of 96% and the sp would have reached new heights IMHO. But this isn't the first time Theralase's sp has taken an unexpected and unwarranted hit.